about
Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestrationThe dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancerRole of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer developmentEpigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle studyMethylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.Long non-coding RNAs as targets for cytosine methylation.Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumorsEpigenetics in the perioperative period.Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patientsExpression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastomaEvaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancerDetection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testingCancer diagnosis, risk assessment and prediction of therapeutic response by means of DNA methylation markers.High prevalence of side population in human cancer cell lines.Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.Ovarian cancer stem cells.miR-21-3p is a positive regulator of L1CAM in several human carcinomas.In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors.KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patientsLidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro.E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery.Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer.Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells.A concept of a MIABIS based register of biosample collections at the Medical University of Innsbruck.Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer.FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3.GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.FBXW7/hCDC4 is a general tumor suppressor in human cancer.Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.DNA hypomethylation and ovarian cancer biology.
P50
Q24295854-CFB5A40F-34B7-4EF6-A010-4E2935658D3DQ28480584-187281F8-3821-4B13-A0C7-BCF4EA4A6C81Q28509811-7A06DEDA-E69B-4170-A99E-FA6488D1D6A3Q33352027-74D56A79-0676-482D-9AB3-AFC005EF00DCQ33827681-7903F503-2C0B-48D6-A16D-6F6FA3B84D5DQ33953005-B30CC335-A638-40FE-8DB9-ACEEFF933B71Q35128002-AD7D7DCB-0205-4959-A5CD-F5375230FF00Q35286762-8CD5D21C-9324-49C5-8AE5-A7DB4854A4B3Q35631463-3A249E84-CF0C-4B4A-A187-93788473425DQ35653787-35B9EA44-FDEB-44C2-A8F1-E9E5EECC8395Q35924210-F447B8E6-0114-4A38-BB1D-FA05487C6293Q35998617-BFBB713D-A4C7-4696-ABF9-90E322CF5EF4Q36093220-E95B3ABF-C494-45E2-AF1C-29A08025FE35Q36172096-00E5CCC9-0B70-420E-9398-323D8CE350E8Q36203121-7CA6C20D-DAF2-41E1-8941-20F4615B70E7Q36413103-04BFEA0C-A6B7-4CCE-BCCA-8FFAC887AA7BQ36474986-B8CB5929-6934-46FE-B4E3-5CF9105F027CQ36746216-1EFC4277-0AE5-4821-A623-6F83AF800B66Q36915997-F1668EFD-2955-44FF-BD0B-557ED6E3A005Q37392946-CD5E8A4A-D369-4216-8322-152BC5BE9D1DQ37457845-ED58453F-E399-445C-AECD-9EADB80DD6F6Q37660308-70FC28D1-9CB0-498D-BB5F-BAB67E0F2A0DQ38031960-E7D24510-7420-49E5-AD01-9B77CCAA16B9Q38963619-92407BA9-6A19-4370-B80D-160865A2CEEEQ38998613-01587C18-635F-4F7A-AF53-AE78CB3DD574Q39195311-4F13E4F8-2C05-4F27-AB2F-CBFFCD3B9A80Q39357207-69660158-4003-4928-B3E0-50C67BA572ACQ39705065-5E7698C8-4138-492C-A4D6-497FF097B592Q39862969-4367F7EA-192E-4DD6-B4D4-CC7F021753F7Q39890756-2E09C25D-8762-4455-832F-6DE350F70C2EQ40253957-5F093B17-58FA-476E-8345-46AE71D82CFAQ40550191-BA473041-5C12-4412-87F8-8240126589F7Q41825885-9A33FD6D-E1A9-4939-9214-DCBC6DF7F551Q42679165-A4041BE5-B13A-4FEC-98D8-59F4B176E66BQ43184300-D4F8F72E-CE20-46DE-A2BE-D75AB9469BFEQ43816387-23985C30-9E62-4EF4-A21E-AE943A7F0C01Q44398514-F1FF65A7-F69D-4291-9B18-71FA796BA72EQ45345209-B258726E-BFC6-414C-BACE-7D40D0A0FB37Q46882661-02279C2C-7A58-4126-A7E5-4FDD52F119B2Q47255043-C54FAB5D-C76A-4D20-9980-DFF9AFD81717
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Heidi Fiegl
@ast
Heidi Fiegl
@en
Heidi Fiegl
@es
Heidi Fiegl
@nl
type
label
Heidi Fiegl
@ast
Heidi Fiegl
@en
Heidi Fiegl
@es
Heidi Fiegl
@nl
prefLabel
Heidi Fiegl
@ast
Heidi Fiegl
@en
Heidi Fiegl
@es
Heidi Fiegl
@nl
P106
P31
P496
0000-0002-1236-6806